These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25108029)

  • 21. Human immunodeficiency virus (HIV) infection during pregnancy induces CD4 T-cell differentiation and modulates responses to Bacille Calmette-Guérin (BCG) vaccine in HIV-uninfected infants.
    Miles DJ; Gadama L; Gumbi A; Nyalo F; Makanani B; Heyderman RS
    Immunology; 2010 Mar; 129(3):446-54. PubMed ID: 20002789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A lipidated bi-epitope vaccine comprising of MHC-I and MHC-II binder peptides elicits protective CD4 T cell and CD8 T cell immunity against Mycobacterium tuberculosis.
    Rai PK; Chodisetti SB; Maurya SK; Nadeem S; Zeng W; Janmeja AK; Jackson DC; Agrewala JN
    J Transl Med; 2018 Oct; 16(1):279. PubMed ID: 30305097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tuberculosis: molecular genetic BCG vaccine preparation].
    Pneumologie; 1997 Aug; 51(8):XIV. PubMed ID: 9380655
    [No Abstract]   [Full Text] [Related]  

  • 24. Accelerating the secondary immune response by inactivating CD4(+)CD25(+) T regulatory cells prior to BCG vaccination does not enhance protection against tuberculosis.
    Quinn KM; Rich FJ; Goldsack LM; de Lisle GW; Buddle BM; Delahunt B; Kirman JR
    Eur J Immunol; 2008 Mar; 38(3):695-705. PubMed ID: 18266274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD8+ regulatory T cells, and not CD4+ T cells, dominate suppressive phenotype and function after in vitro live Mycobacterium bovis-BCG activation of human cells.
    Boer MC; van Meijgaarden KE; Joosten SA; Ottenhoff TH
    PLoS One; 2014; 9(4):e94192. PubMed ID: 24714620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles.
    Soares AP; Scriba TJ; Joseph S; Harbacheuski R; Murray RA; Gelderbloem SJ; Hawkridge A; Hussey GD; Maecker H; Kaplan G; Hanekom WA
    J Immunol; 2008 Mar; 180(5):3569-77. PubMed ID: 18292584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accelerated induction of mycobacterial antigen-specific CD8+ T cells in the Mycobacterium tuberculosis-infected lung by subcutaneous vaccination with Mycobacterium bovis bacille Calmette-Guérin.
    Begum D; Umemura M; Yahagi A; Okamoto Y; Hamada S; Oshiro K; Matsuzaki G
    Immunology; 2009 Dec; 128(4):556-63. PubMed ID: 19930045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TCR repertoire, clonal dominance, and pulmonary trafficking of mycobacterium-specific CD4+ and CD8+ T effector cells in immunity against tuberculosis.
    Du G; Chen CY; Shen Y; Qiu L; Huang D; Wang R; Chen ZW
    J Immunol; 2010 Oct; 185(7):3940-7. PubMed ID: 20805423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancement of antimycobacterial Th1-cell responses by a Mycobacterium bovis BCG prime-protein boost vaccination strategy.
    Lu M; Xia ZY; Bao L
    Cell Immunol; 2013; 285(1-2):111-7. PubMed ID: 24177251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical development of BCG.HIVA
    Mahant A; Saubi N; Eto Y; Guitart N; Gatell JM; Hanke T; Joseph J
    Hum Vaccin Immunother; 2017 Aug; 13(8):1798-1810. PubMed ID: 28426273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors.
    Hopkins R; Bridgeman A; Bourne C; Mbewe-Mvula A; Sadoff JC; Both GW; Joseph J; Fulkerson J; Hanke T
    Eur J Immunol; 2011 Dec; 41(12):3542-52. PubMed ID: 21932450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
    Scriba TJ; Tameris M; Mansoor N; Smit E; van der Merwe L; Mauff K; Hughes EJ; Moyo S; Brittain N; Lawrie A; Mulenga H; de Kock M; Gelderbloem S; Veldsman A; Hatherill M; Geldenhuys H; Hill AV; Hussey GD; Mahomed H; Hanekom WA; McShane H
    J Infect Dis; 2011 Jun; 203(12):1832-43. PubMed ID: 21606542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining.
    Smith SG; Lalor MK; Gorak-Stolinska P; Blitz R; Beveridge NE; Worth A; McShane H; Dockrell HM
    BMC Immunol; 2010 Jul; 11():35. PubMed ID: 20609237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire.
    Casazza JP; Bowman KA; Adzaku S; Smith EC; Enama ME; Bailer RT; Price DA; Gostick E; Gordon IJ; Ambrozak DR; Nason MC; Roederer M; Andrews CA; Maldarelli FM; Wiegand A; Kearney MF; Persaud D; Ziemniak C; Gottardo R; Ledgerwood JE; Graham BS; Koup RA;
    J Infect Dis; 2013 Jun; 207(12):1829-40. PubMed ID: 23482645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparable CD4 and CD8 T cell responses and cytokine release after at-birth and delayed BCG immunisation in infants born in Australia.
    Ritz N; Casalaz D; Donath S; Tebruegge M; Dutta B; Connell TG; Robins-Browne R; Britton WJ; Hanekom WA; Curtis N
    Vaccine; 2016 Jul; 34(35):4132-4139. PubMed ID: 27396518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prime-boost vaccination strategy with bacillus Calmette-Guérin (BCG) and liposomized alpha-crystalline protein 1 reinvigorates BCG potency.
    Siddiqui KF; Amir M; Khan N; Rama Krishna G; Sheikh JA; Rajagopal K; Agrewala JN
    Clin Exp Immunol; 2015 Aug; 181(2):286-96. PubMed ID: 25845290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.
    Tameris M; Hokey DA; Nduba V; Sacarlal J; Laher F; Kiringa G; Gondo K; Lazarus EM; Gray GE; Nachman S; Mahomed H; Downing K; Abel B; Scriba TJ; McClain JB; Pau MG; Hendriks J; Dheenadhayalan V; Ishmukhamedov S; Luabeya AK; Geldenhuys H; Shepherd B; Blatner G; Cardenas V; Walker R; Hanekom WA; Sadoff J; Douoguih M; Barker L; Hatherill M
    Vaccine; 2015 Jun; 33(25):2944-54. PubMed ID: 25936724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of cross-priming of naive CD8+ T lymphocytes by recombinant bacillus Calmette-Guerin that secretes heat shock protein 70-major membrane protein-II fusion protein.
    Mukai T; Maeda Y; Tamura T; Matsuoka M; Tsukamoto Y; Makino M
    J Immunol; 2009 Nov; 183(10):6561-8. PubMed ID: 19846882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Current advances in HIV pathogenesis. Results of therapy and vaccine development].
    Wagner R; Mayer J; Wolf H
    Dtsch Med Wochenschr; 1995 May; 120(20):728-36. PubMed ID: 7758413
    [No Abstract]   [Full Text] [Related]  

  • 40. Stimulation of human peripheral blood mononuclear cells with live Mycobacterium bovis BCG activates cytolytic CD8+ T cells in vitro.
    Turner J; Dockrell HM
    Immunology; 1996 Mar; 87(3):339-42. PubMed ID: 8778016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.